Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlink™ technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.
Mablink is currently developing three ADC programs based on a camptothecin derivative (a topoisomerase I inhibitor) as payload:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
MBK-103
Solid Tumors
Preclinical
MBK-102
Multiple Myeloma / Lymphomas
Preclinical
MBK-101
Acute Myeloid Leukemia
Preclinical